MK-2866, also known as ostarine or enobosarm, is an experimental drug that selectively activates androgen receptors in muscle and bone tissue to promote growth, similar to testosterone but with fewer effects on other organs. It was developed to treat conditions like muscle wasting in cancer patients and age-related muscle loss, but it has never been approved by the FDA for any use. Here’s what clinical trials and research actually show about its effects.
How MK-2866 Works in the Body
MK-2866 belongs to a class of compounds called selective androgen receptor modulators, or SARMs. It enters cells and binds to the androgen receptor, the same receptor that testosterone activates. Once bound, the receptor-drug complex moves into the cell’s nucleus and switches on genes responsible for building muscle and maintaining bone.
The key word is “selective.” Testosterone affects tissues throughout the body, including the prostate, skin, and hair follicles. MK-2866 was designed to preferentially target muscle and bone while producing less activity in other tissues. This tissue selectivity is what separates SARMs from traditional anabolic steroids in theory, though the selectivity is not absolute.
Effects on Muscle Mass
Several clinical trials have tested MK-2866 in humans, and the muscle-building effects are modest but measurable. In a Phase 2 trial of 120 older men and postmenopausal women, those taking a 3 mg daily dose gained an average of 1.25 kg (about 2.75 lbs) of lean body mass over 12 weeks, while the placebo group lost 0.70 kg. Lower doses produced smaller, statistically insignificant gains.
In cancer patients experiencing muscle wasting, similar results appeared. A 16-week trial of 159 patients found that a 1 mg dose produced a 1.5 kg increase in lean mass compared to baseline, and a 3 mg dose produced a 1.3 kg increase. Two larger Phase 3 trials in lung cancer patients on chemotherapy confirmed the pattern: patients on 3 mg of MK-2866 gained roughly half a kilogram of lean mass over 21 weeks, while placebo groups continued losing muscle.
These numbers are significant for people losing muscle to disease or aging, but they’re far smaller than what anabolic steroids produce. The gains also came with modest fat loss. In the 12-week trial of older adults, the 3 mg group lost 0.32 kg of fat mass compared to a slight fat gain in the placebo group.
Effects on Bone
Animal research suggests MK-2866 can help maintain bone density. In studies on rats with surgically reduced testosterone (a model for osteoporosis), MK-2866 given as a preventive treatment maintained spinal bone mineral density at levels higher than untreated animals, and even improved density compared to animals with normal hormone levels after 18 weeks. It also improved the cortical density of the thighbone, which is the dense outer layer that gives bones their structural strength.
MK-2866 appeared to slow bone turnover. Treated animals showed significantly lower levels of osteocalcin, a marker of bone remodeling, suggesting the drug reduced the excessive bone breakdown that occurs when androgen levels drop. Human bone density data from clinical trials is limited, however, and no trials have been completed specifically for osteoporosis treatment in people.
Hormonal Suppression
MK-2866 interferes with the hormonal feedback loop between the brain and the gonads. When the body detects androgen-like activity from MK-2866, it can reduce its own testosterone production. This means that while taking MK-2866, your natural testosterone levels may drop. The extent of suppression appears to be dose-dependent, and recovery timelines after stopping are not well characterized in published data.
This suppression is one of the main concerns with unsupervised use. People who stop taking MK-2866 may experience a period of low testosterone, with symptoms like fatigue, reduced sex drive, and mood changes, until their natural production recovers.
Liver and Cardiovascular Risks
Liver injury is a documented risk. Case reports have linked MK-2866 use to elevated liver enzymes, the markers doctors use to assess liver stress. In one published case, a user presented with ALT levels roughly three times the normal upper limit. While liver enzymes typically normalize within three to twelve months after stopping the drug, more severe liver injury, including acute liver failure, has been reported with SARMs as a class.
The FDA has issued a public warning stating that SARMs, including MK-2866, are associated with increased risk of heart attack or stroke, liver injury and acute liver failure, sexual dysfunction, infertility, testicular shrinkage, sleep disturbances, and even psychosis or hallucinations. These warnings are based on adverse event reports and post-market surveillance, not just clinical trial data, so they reflect what happens when people use these products without medical supervision, often at higher doses and for longer durations than studied in trials.
Legal and Regulatory Status
MK-2866 is not approved by the FDA for any medical use. It cannot legally be sold as a dietary supplement or marketed as a drug in the United States. Products containing it are classified as unapproved drugs. Despite this, it is widely sold online, often labeled “for research purposes only,” a legal gray area that allows vendors to sidestep drug regulations.
The World Anti-Doping Agency banned ostarine in 2008 under class S1.2 (“other anabolic agents”), prohibiting it both in and out of competition. It is one of the most frequently detected substances in anti-doping violations. The drug can be identified in urine, hair, nail clippings, and sweat, and even appears in oral fluid for at least 8 hours after a single dose. Athletes have tested positive after using contaminated supplements that contained undeclared ostarine, making it a particular hazard for anyone subject to drug testing.
Investigational Medical Uses
Beyond muscle wasting, researchers are exploring MK-2866 for stress urinary incontinence in postmenopausal women. The rationale is straightforward: pelvic floor muscles weaken with age and declining hormone levels, contributing to bladder control problems. Because MK-2866 promotes muscle growth in a tissue-selective way, it could theoretically strengthen pelvic floor muscles without the side effects of testosterone therapy. A Mayo Clinic trial is evaluating this application, though results have not yet been published.
There is also an ongoing Phase 2 trial studying MK-2866 alongside semaglutide (the active ingredient in Ozempic and Wegovy) to see whether it can preserve lean muscle mass during weight loss. GLP-1 drugs cause significant fat loss but also strip away muscle, and MK-2866 is being tested as a potential countermeasure. That trial is enrolling an estimated 150 older adults over 16 weeks.